Exact Sciences (EXAS) | Financial Analysis & Statements
Exact Sciences Corp Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
878.4M
Gross Profit
615.8M
70.11%
Operating Income
-82.2M
-9.36%
Net Income
-86.0M
-9.79%
Balance Sheet Metrics
Total Assets
5.9B
Total Liabilities
3.5B
Shareholders Equity
2.4B
Debt to Equity
1.44
Cash Flow Metrics
Operating Cash Flow
98.7M
Free Cash Flow
120.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Exact Sciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.2B | 2.8B | 2.5B | 2.1B | 1.8B |
| Cost of Goods Sold | 984.2M | 840.2M | 654.2M | 574.4M | 458.8M |
| Gross Profit | 2.3B | 1.9B | 1.8B | 1.5B | 1.3B |
| Gross Margin % | 69.7% | 69.5% | 73.8% | 72.4% | 74.0% |
| Operating Expenses | |||||
| Research & Development | 523.0M | 431.2M | 425.9M | 393.4M | 385.6M |
| Selling, General & Administrative | 1.9B | 1.7B | 1.6B | 1.6B | 1.7B |
| Other Operating Expenses | - | -9.2M | -78.4M | 13.2M | - |
| Total Operating Expenses | 2.5B | 2.1B | 2.0B | 2.0B | 2.0B |
| Operating Income | -199.1M | -179.1M | -214.3M | -577.5M | -835.5M |
| Operating Margin % | -6.1% | -6.5% | -8.6% | -27.7% | -47.3% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 34.8M | 32.0M | 24.4M | 13.9M | 12.9M |
| Other Non-Operating Income | 34.6M | -819.6M | 42.4M | -35.4M | 11.6M |
| Pre-tax Income | -203.9M | -1.0B | -201.7M | -632.6M | -842.5M |
| Income Tax | 4.1M | -7.3M | 2.4M | -9.1M | -246.9M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -207.9M | -1.0B | -204.1M | -623.5M | -595.6M |
| Net Margin % | -6.4% | -37.3% | -8.2% | -29.9% | -33.7% |
| Key Metrics | |||||
| EBITDA | 17.9M | 30.3M | -13.1M | -385.7M | -660.8M |
| EPS (Basic) | $-1.10 | $-5.59 | $-1.13 | $-3.54 | $-3.48 |
| EPS (Diluted) | $-1.10 | $-5.59 | $-1.13 | $-3.54 | $-3.48 |
| Basic Shares Outstanding | 188688000 | 184197000 | 180144000 | 176351000 | 171348000 |
| Diluted Shares Outstanding | 188688000 | 184197000 | 180144000 | 176351000 | 171348000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Exact Sciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 956.0M | 600.9M | 605.4M | 242.5M | 315.5M |
| Short-term Investments | 8.7M | 437.1M | 172.3M | 389.6M | 715.0M |
| Accounts Receivable | 298.7M | 249.0M | 203.6M | 158.0M | 216.6M |
| Inventory | 166.2M | 162.4M | 127.5M | 118.3M | 105.0M |
| Other Current Assets | 126.3M | 122.0M | 85.6M | 73.9M | 74.1M |
| Total Current Assets | 1.6B | 1.6B | 1.2B | 982.3M | 1.4B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 122.3M | 117.0M | 143.7M | 167.0M | 364.0M |
| Goodwill | 5.7B | 5.7B | 6.6B | 6.6B | 6.8B |
| Intangible Assets | 919.9M | 1.0B | 1.9B | 2.0B | 2.1B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 185.8M | 169.7M | 177.4M | 90.6M | 74.6M |
| Total Non-Current Assets | 4.3B | 4.4B | 5.3B | 5.2B | 5.3B |
| Total Assets | 5.9B | 5.9B | 6.5B | 6.2B | 6.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 175.9M | 89.6M | 78.8M | 74.9M | 67.8M |
| Short-term Debt | 33.6M | 276.6M | 79.4M | 28.4M | 19.7M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 15.2M | 37.8M | 14.8M | 10.2M | 31.0M |
| Total Current Liabilities | 641.2M | 732.2M | 514.7M | 412.7M | 517.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.5B | 2.5B | 2.5B | 2.4B | 2.4B |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 329.3M | 315.5M | 336.0M | 352.5M | 417.8M |
| Total Non-Current Liabilities | 2.8B | 2.8B | 2.8B | 2.8B | 2.8B |
| Total Liabilities | 3.5B | 3.5B | 3.3B | 3.2B | 3.3B |
| Equity | |||||
| Common Stock | 1.9M | 1.9M | 1.8M | 1.8M | 1.7M |
| Retained Earnings | -4.7B | -4.5B | -3.5B | -3.3B | -2.6B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.4B | 2.4B | 3.1B | 3.0B | 3.4B |
| Key Metrics | |||||
| Total Debt | 2.5B | 2.8B | 2.6B | 2.4B | 2.4B |
| Working Capital | 914.7M | 839.2M | 679.7M | 569.5M | 909.2M |
Balance Sheet Composition
Exact Sciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -207.9M | -1.0B | -204.1M | -623.5M | -595.6M |
| Depreciation & Amortization | 221.6M | 214.9M | 206.6M | 197.6M | 180.3M |
| Stock-Based Compensation | 217.7M | 214.9M | 231.3M | 206.8M | 253.1M |
| Working Capital Changes | -92.2M | -99.6M | -83.1M | 24.4M | -58.7M |
| Operating Cash Flow | 273.3M | -694.9M | 87.2M | -223.8M | -268.9M |
| Investing Activities | |||||
| Capital Expenditures | -134.7M | -136.0M | -124.2M | -214.5M | -135.8M |
| Acquisitions | 0 | 0 | -69.0M | -57.5M | -517.8M |
| Investment Purchases | -195.8M | -466.8M | -139.9M | -131.5M | -1.2B |
| Investment Sales | 572.3M | 205.8M | 383.0M | 453.1M | 794.3M |
| Investing Cash Flow | 195.1M | -442.2M | 49.7M | 74.1M | -1.1B |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 266.8M | 138.0M | 50.0M | 0 |
| Debt Repayment | -249.2M | -50.0M | 0 | 0 | -23.7M |
| Financing Cash Flow | -366.5M | 199.0M | 128.2M | 44.5M | -29.0M |
| Free Cash Flow | 356.8M | 74.5M | 31.9M | -438.0M | -238.0M |
| Net Change in Cash | 101.9M | -938.1M | 265.1M | -105.2M | -1.4B |
Cash Flow Trend
Exact Sciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-95.37
Forward P/E
55.22
Price to Book
8.34
Price to Sales
6.17
PEG Ratio
55.22
Profitability Ratios
Profit Margin
-6.40%
Operating Margin
-9.28%
Return on Equity
-8.66%
Return on Assets
-1.59%
Financial Health
Current Ratio
2.43
Debt to Equity
105.57
Beta
1.44
Per Share Data
EPS (TTM)
$-1.10
Book Value per Share
$12.58
Revenue per Share
$17.21
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| EXAS | 20.0B | -95.37 | 8.34 | -8.66% | -6.40% | 105.57 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Idexx Laboratories | 44.7B | 42.92 | 27.85 | 66.20% | 24.62% | 60.83 |
| Agilent Technologies | 32.7B | 25.67 | 4.76 | 19.95% | 18.26% | 51.39 |
| Waters | 30.5B | 28.90 | 7.24 | 29.28% | 20.30% | 60.28 |
Financial data is updated regularly. All figures are in the company's reporting currency.






